Abliva AB Interim Report January – March 2023
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Press releases
Abliva AB Year-End Report January – December 2022
A successful financing enabled the start of the FALCON study with KL1333
Abliva AB Interim Report January – September 2022
Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Abliva AB Interim Report January – June 2022
SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Abliva AB Interim Report January – March 2022
First quarter summary
Abliva AB Year-End Report January – December 2021
"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO
Abliva AB Interim Report January – September 2021
Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Abliva AB Interim Report January – June 2021
Second quarter summary
Abliva AB Interim Report January – March 2021
First quarter summary
Abliva AB Year-End Report January – December 2020
2020 summary
Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner